

Electronic Acknowledgement Receipt

EFS ID:	1726400
Application Number:	10728521
International Application Number:	
Confirmation Number:	8270
Title of Invention:	Oral lactoferrin in the treatment of sepsis
First Named Inventor/Applicant Name:	Atul Varadhachary
Customer Number:	26271
Filer:	Allen Eugene White
Filer Authorized By:	
Attorney Docket Number:	HO-P02703US2
Receipt Date:	30-APR-2007
Filing Date:	05-DEC-2003
Time Stamp:	18:08:23
Application Type:	Utility

Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	1029
Deposit Account	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)
-----------------	----------------------	-----------	------------------	------------------	------------------

1	Information Disclosure Statement (IDS) Filed	HOP02703US2_SIDS.pdf	28013	no	2
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
2	Information Disclosure Statement (IDS) Filed	HOP02703US2_SIDS_by_Aplicant.pdf	67131	no	4
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
3	Foreign Reference	WO92021752.pdf	4201047	no	66
Warnings:					
Information:					
4	Foreign Reference	EP0584558A2.pdf	641523	no	10
Warnings:					
Information:					
5	Foreign Reference	JP7233086A.pdf	919399	no	13
Warnings:					
Information:					
6	Foreign Reference	EP0730868.pdf	392265	no	7
Warnings:					
Information:					
7	Foreign Reference	WO9833509.pdf	2738519	no	71
Warnings:					
Information:					
8	Foreign Reference	WO0203910.pdf	1777872	no	35
Warnings:					
Information:					

9	Foreign Reference	WO02100445A1.pdf	1641211	no	31
Warnings:					
Information:					
10	NPL Documents	Arnold_Bactericidal.pdf	568634	no	7
Warnings:					
Information:					
11	NPL Documents	Artym_Lactoferrin.pdf	25691	no	1
Warnings:					
Information:					
12	NPL Documents	Artym_Normalization.pdf	433669	no	6
Warnings:					
Information:					
13	NPL Documents	Artym_Orally.pdf	478009	no	7
Warnings:					
Information:					
14	NPL Documents	Artym_Reconstitution.pdf	639345	no	9
Warnings:					
Information:					
15	NPL Documents	Bellamy_Killing.pdf	591487	no	9
Warnings:					
Information:					
16	NPL Documents	Brink.pdf	581501	no	7
Warnings:					
Information:					
17	NPL Documents	Clarke_Evaluation.pdf	418621	no	6
Warnings:					
Information:					

18	NPL Documents	Cumberbatch_IL-1.pdf	605556	no	8
Warnings:					
Information:					
19	NPL Documents	Cumberbatch_Regulation.pdf	711722	no	8
Warnings:					
Information:					
20	NPL Documents	Dial_Effect.pdf	518246	no	5
Warnings:					
Information:					
21	NPL Documents	Donnelly_Antimicrobial.pdf	1292643	no	9
Warnings:					
Information:					
22	NPL Documents	Ellison_Damage.pdf	788224	no	8
Warnings:					
Information:					
23	NPL Documents	Fujihara.pdf	384025	no	5
Warnings:					
Information:					
24	NPL Documents	Harmsen_Antiviral.pdf	854385	no	9
Warnings:					
Information:					
25	NPL Documents	He.pdf	823068	no	9
Warnings:					
Information:					
26	NPL Documents	Ikeda_Lactoferrin.pdf	421722	no	5
Warnings:					
Information:					

27	NPL Documents	Inoue_Ref.pdf	186192	no	3
Warnings:					
Information:					
28	NPL Documents	Isamida_Protective.pdf	258136	no	4
Warnings:					
Information:					
29	NPL Documents	Kimber_Lactoferrin_and_Regulation.pdf	443511	no	7
Warnings:					
Information:					
30	NPL Documents	Kimber_Lactoferrin.pdf	462498	no	5
Warnings:					
Information:					
31	NPL Documents	Kuipers_Synergistic.pdf	745687	no	7
Warnings:					
Information:					
32	NPL Documents	Legrand.pdf	532746	no	7
Warnings:					
Information:					
33	NPL Documents	Levay_lactoferrin.pdf	1215935	no	16
Warnings:					
Information:					
34	NPL Documents	Makkonen_Granulocyte.pdf	894744	no	10
Warnings:					
Information:					
35	NPL Documents	Marchetti_Metal.pdf	455248	no	6
Warnings:					
Information:					

36	NPL Documents	Masson_Lactoferrin.pdf	800681	no	14
Warnings:					
Information:					
37	NPL Documents	Matthews.pdf	277693	no	3
Warnings:					
Information:					
38	NPL Documents	Metz_Boutigue_Human.pdf	1022945	no	18
Warnings:					
Information:					
39	NPL Documents	Miehlke_Direct.pdf	144875	no	2
Warnings:					
Information:					
40	NPL Documents	Nakajima.pdf	474579	no	5
Warnings:					
Information:					
41	NPL Documents	Sato.pdf	297839	no	4
Warnings:					
Information:					
42	NPL Documents	Shih_A_Research.pdf	1606378	no	16
Warnings:					
Information:					
43	NPL Documents	Takakura_Effect.pdf	486244	no	6
Warnings:					
Information:					
44	NPL Documents	Takakura_Oral.pdf	462826	no	5
Warnings:					
Information:					

45	NPL Documents	Takayama_Effects.pdf	480394	no	6
Warnings:					
Information:					
46	NPL Documents	Takayama_Bovine.pdf	527316	no	5
Warnings:					
Information:					
47	NPL Documents	Tomita_Potent.pdf	549712	no	6
Warnings:					
Information:					
48	NPL Documents	Trumpler_Antibacterial.pdf	306474	no	4
Warnings:					
Information:					
49	NPL Documents	Van_Berkel.pdf	322440	no	7
Warnings:					
Information:					
50	NPL Documents	Vorland_Lactoferrin.pdf	934333	no	11
Warnings:					
Information:					
51	NPL Documents	Ward_A_System.pdf	726852	no	6
Warnings:					
Information:					
52	NPL Documents	Ward_Lactoferrin.pdf	879276	no	8
Warnings:					
Information:					
53	NPL Documents	Weinberg.pdf	1021586	no	11
Warnings:					
Information:					

54	NPL Documents	Yamaguchi_Potential.pdf	274318	no	4
Warnings:					
Information:					
55	NPL Documents	Yang_Antitumor.pdf	1153402	no	12
Warnings:					
Information:					
56	NPL Documents	Yang_Enhanced.pdf	920755	no	11
Warnings:					
Information:					
57	NPL Documents	Kuhara_Nutrition_and_Cancer_2000.pdf	1022965	no	8
Warnings:					
Information:					
58		10728521_response_30-april-07_nfoa_06-dec-06.pdf	68182	yes	6
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment - After Non-Final Rejection		1	1	
	Applicant Arguments/Remarks Made in an Amendment		2	6	
Warnings:					
Information:					
59	Fee Worksheet (PTO-06)	fee-info.pdf	8163	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			42508453		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.